バージニアにおける片頭痛の臨床試験
バージニア内の拠点で、片頭痛に関する7件の研究が参加者を募集しています。
バージニア内の都市
公式研究テキスト（英語）
Study of EVO756 in Adults With Migraine
- MedStar Health: Headache Center at McLean, McLean
被験者募集中第2相
18歳〜64歳 · 全性別 · 2026/10/02更新 · NCT07616128Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Pediatric Associates of Charlottesville, PLC (Private Pediatric Practice), Charlottesville
- Pediatric Research of Charlottesville, LLC (Regulatory Only), Charlottesville
- Pediatric Research of Charlottesville, LLC, Charlottesville
- 他2件
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/24更新 · NCT04743141Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Pediatric Associates of Charlottesville, PLC (Private Pediatric Practice), Charlottesville
- Pediatric Research of Charlottesville, LLC (Regulatory Only), Charlottesville
- Pediatric Research of Charlottesville, LLC, Charlottesville
- 他2件
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/24更新 · NCT04649242Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Pediatric Associates of Charlottesville, PLC /ID# 230628, Charlottesville
- Children's Hospital of The King's Daughters - Children's Medical Tower /ID# 230581, Norfolk
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/14更新 · NCT05125302A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Health Research of Hampton Roads, Inc. (HRHR), Newport News
- AMR Clinical - Norfolk, Norfolk
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/08/20更新 · NCT07645924A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
- Children's Specialty Group - 3 Commercial Place, Norfolk
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/06/12更新 · NCT05164172Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
- MedStar Health: Neurology at McLean, McLean
被験者募集中第4相
18歳以上 · 全性別 · 2025/12/24更新 · NCT07301008ClinicalTrials.govより、2026/10/04時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。